Status:
RECRUITING
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Hvidovre University Hospital
Conditions:
Chronic Liver Disease
Eligibility:
All Genders
18+ years
Brief Summary
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other...
Eligibility Criteria
Inclusion
- Adult patients/healthy control participants (age 18 or above) who can give their informed consent
- Suspected liver disease:
- non-alcoholic steatohepatitis
- alcoholic steatohepatitis
- autoimmune hepatitis
- primary biliary cholangitis
- primary sclerosing cholangitis
- inflammatory bowel disease
- polycystic ovary syndrome
- hereditary haemochromatosis
- chronic pancreatitis
- cystic fibrosis
- alpha-1 antitrypsin deficiency
Exclusion
- Patients with:
- malignant diseases
- viral hepatitis
- human immunodeficiency virus
- contraindications to liver biopsy
Key Trial Info
Start Date :
August 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2036
Estimated Enrollment :
335 Patients enrolled
Trial Details
Trial ID
NCT05335603
Start Date
August 24 2020
End Date
August 1 2036
Last Update
April 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hvidovre University Hospital
Hvidovre, Denmark, 2650